Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fibre Neuropathy That Is Idiopathic or Associated With Diabetes Mellitus

Next Previous
Trial Profile

A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fibre Neuropathy That Is Idiopathic or Associated With Diabetes Mellitus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Biogen

    • Most Recent Events

    • 09 May 2018 Status changed from not yet recruiting to recruiting.
    • 24 Jan 2018 Planned End Date changed from 1 Jul 2019 to 27 Aug 2020.
    • 24 Jan 2018 Planned primary completion date changed from 1 Jul 2019 to 27 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top